RE:RE:RE:RE:Kedrion option extension announced 2 days late What I want to know is how after 3 years or more, Newcamo / Realstocky still can't spell Ryplazim? I guess he can't spell gonna (gona), sure (sur) and u're (you're) and got (gat) either.
I don't think he's ever read an analyst report and couldn't tell you what portion of Piper Sandler price target was IPF (a heck of a lot for sales in US and Euro). Poof, they put it out there in front of liver, heart and kidney as their best potential and poof, another 12-18 month delay and probably more with Liminal track record (see Ryplazim 6 months to do 4 quick checkpoints and took 3 years).
Newcamo wrote: nothing changed, i would prefer we keep riplazym, even if it means a small financing, but if kedrion wants to go through like it looks like it is, 100M$ would do wonders to the sp and business plan...
GunnerG wrote: Stups, you just jumped on the band wagon yesterday. Today your off and we are now selling again. ROF Make up your mind doofus. Your response to your other ID:
I think the same man! Like i said, I hope we keep riplazym! Cant wait to read the spammers if we do! After saying a million times we gave away the golden goose. In fact we had a good deal (100M$), but riplazym is a real business with recurring good revenues... they are hiring people to launch it! So looks good.
We will know soon.
Newcamo wrote: i really wish the deal with kedrion doesnt go through, and lmnl keeps riplazym! 100M$ is nice but mid term, LMNL would make a lot more commercialising riplazym... they are hiring production people, lets see! Personnally im loading up...
realstocky wrote: what are u babbling about, its paper work delays, who cares:) the deal is obviously going forward if they extended it for a week. Good news. Is some other news responsable for that lil delay?
stockbuphoon wrote:
This is just a rookie management team or doing this stuff on purpose which is even more evil.
This Report on Form 6-K (the “Report”) is hereby expressly incorporated by reference into the registrant’s registration statements on Form F-3 (File nos. 333-251055, 333-245703 and 333-251065) filed with the Securities and Exchange Commission on December 1, 2020, December 2, 2020 and December 2, 2020, respectively, and the registration statement on Form S-8 (File no. 333-235692) filed with the Securities and Exchange Commission on December 23, 2019.
Extension of the Option Agreement entered into between Liminal BioSciences Inc. and Kedrion S.p.A.
Liminal Biosciences Inc. (the “Company”) today announced that it has amended the Option Agreement it entered into with Kedrion S.p.A. on May 21, 2021 to extend the option exercise period under such Option Agreement from June 15, 2021 to June 22, 2021.